Patents by Inventor Kenji Fukunaga

Kenji Fukunaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210160979
    Abstract: A lighting control system includes: a light fixture including a first light emitting device configured to emit light having a correlated color temperature in the range of ±500 K from a prescribed value, a second light emitting device configured to emit light having a correlated color temperature in the range of ±500 K from the prescribed value, and an emission controller configured to cause the light fixture to irradiate illumination light by controlling irradiation percentages of the light emitted from the first light emitting device and the light emitted from the second light emitting device; and an information processing apparatus communicably connected to the light fixture, the information processing apparatus comprising a dimming controller configured to change the irradiation percentages of the light emitted from the first light emitting device and the second light emitting device in accordance with a time of day by transmitting dimming instructions.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Applicant: NICHIA CORPORATION
    Inventors: Kei HARAGUCHI, Kenji ASAI, Munetake FUKUNAGA, Yasuo FUJIKAWA
  • Patent number: 10793582
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 6, 2020
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Nobuaki Fujimoto
  • Publication number: 20190233438
    Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.
    Type: Application
    Filed: October 21, 2016
    Publication date: August 1, 2019
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Nobuaki FUJIMOTO
  • Patent number: 10065972
    Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 4, 2018
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro Okuyama, Kenji Fukunaga, Kenji Usui, Norimitsu Hayashi, Daisuke Iijima, Hideki Horiuchi, Noriaki Itagaki
  • Patent number: 9735906
    Abstract: A demultiplexing device includes a first demultiplexer configured to demultiplex a first input signal, a second demultiplexer configured to demultiplex a second input signal, and a switching circuit configured to set an input destination of signals demultiplexed and output by each of the first demultiplexer and the second demultiplexer based on data rates of the first and second input signals. A multiplexing device includes a first multiplexer configured to multiplex a first input signal, a second multiplexer configured to multiplex a second input signal, and a switching circuit configured to set an input destination of signals multiplexed and output by the first multiplexer and the second multiplexer based on data rates of the first and second input signals.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 15, 2017
    Assignee: FUJITSU LIMITED
    Inventors: Masao Sugahara, Kenji Fukunaga, Koji Komatsu
  • Publication number: 20160376289
    Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2015
    Publication date: December 29, 2016
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Noriaki ITAGAKI
  • Publication number: 20160050042
    Abstract: A demultiplexing device includes: a first demultiplexer configured to demultiplex a first input signal; a second demultiplexer configured to demultiplex a second input signal; and a switching unit configured to set an input destination of signals demultiplexed by each of the first demultiplexer and the second demultiplexer to one of the first demultiplexer and the second demultiplexer, based on a configuration of each of the first input signal and the second input signal.
    Type: Application
    Filed: July 16, 2015
    Publication date: February 18, 2016
    Applicant: FUJITSU LIMITED
    Inventors: Masao SUGAHARA, Kenji FUKUNAGA, Koji KOMATSU
  • Patent number: 9248408
    Abstract: In a hollow fiber element constituting a separation membrane module for separating an organic vapor, at least one end part of a fiber bundle consisting of multiple hollow fiber membranes having a selective permeability is fixed and bound with a tube sheet formed by a cured material, in which an epoxy composition (A) has been cured by using a hardener (B). A glass transition temperature of said cured material is not less than 160° C., a minimum elongation at break thereof is not less than 7.0%, and an elution ratio thereof is less than 5%. For this reason, the hollow fiber element has enough endurance to retain a gas-tightness of an internal space of the hollow fiber membrane and an external space of the hollow fiber membrane even in use under organic vapor with an elevated temperature and high pressure.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 2, 2016
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Tomonori Kanougi, Yuma Irisa, Kenji Fukunaga
  • Patent number: 9211497
    Abstract: An asymmetric gas separation membrane made of an aromatic polyimide mainly containing repeating units having an ether bond which is heated at a temperature near a softening point (Ts) of the aromatic polyimide, and a method for separating methanol from a methanol-containing mixed organic vapor by allowing methanol to selectively permeate the asymmetric gas separation membrane using the membrane.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: December 15, 2015
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Ryoichi Takada, Harutoshi Hoshino, Tomonori Kanougi, Toshimune Yoshinaga, Kenji Fukunaga
  • Patent number: 9029541
    Abstract: A novel binuclear metal complex containing a biimidazole as a bridging ligand. The binuclear metal complex can be used as a material for an organic electroluminescence element.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: May 12, 2015
    Assignee: Ube Industries, Ltd.
    Inventors: Osamu Fujimura, Kenji Fukunaga, Takafumi Iwasa, Yasuhiro Tanaka, Harunori Fujita, Tadashi Murakami, Takashi Honma, Toshikazu Machida, Natsuko Kashihara
  • Publication number: 20130319229
    Abstract: An asymmetric gas separation membrane made of an aromatic polyimide mainly containing repeating units having an ether bond which is heated at a temperature near a softening point (Ts) of the aromatic polyimide, and a method for separating methanol from a methanol-containing mixed organic vapor by allowing methanol to selectively permeate the asymmetric gas separation membrane using the membrane.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 5, 2013
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Ryoichi Takada, Harutoshi Hoshino, Tomonori Kanougi, Toshimune Yoshinaga, Kenji Fukunaga
  • Publication number: 20130324733
    Abstract: A novel binuclear metal complex containing a biimidazole as a bridging ligand. The binuclear metal complex can be used as a material for an organic electroluminescence element.
    Type: Application
    Filed: December 2, 2011
    Publication date: December 5, 2013
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Osamu Fujimura, Kenji Fukunaga, Takafumi Iwasa, Yasuhiro Tanaka, Harunori Fujita, Tadashi Murakami, Takashi Honma, Toshikazu Machida, Natsuko Kashihara
  • Patent number: 8592417
    Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein each R1 represents hydrogen atom or the like; X represents oxygen atom or the like; A represents a C3-C7 cycloalkyl group, a C6-C10 aryl group or a heterocyclic group; R6 represents a halogen atom or the like; s represents 0 or an integer of 1 to 5; Q represents a pyridine ring which may be substituted or pyrimidine ring; and R2 represents hydrogen atom or the like, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: November 26, 2013
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi
    Inventors: Kazutoshi Watanabe, Toshiyuki Kohara, Kenji Fukunaga, Fumiaki Uehara
  • Patent number: 8580012
    Abstract: An asymmetric hollow fiber gas separation membrane obtained by subjecting an asymmetric hollow fiber polyimide membrane to a heat treatment having a maximum temperature of from 350 to 450° C., wherein the asymmetric hollow fiber polyimide membrane is formed with a polyimide essentially having a repeating unit represented by a general formula (1); is excellent in a solvent resistance and a thermal stability, and as well has such a mechanical strength that a tensile elongation at break is not less than 10% as a hollow fiber membrane.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: November 12, 2013
    Assignee: Ube Industries, Ltd.
    Inventors: Harutoshi Hoshino, Tomonori Kanougi, Toshimune Yoshinaga, Yoji Kase, Kenji Fukunaga
  • Patent number: 8569294
    Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: October 29, 2013
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi
    Inventors: Kenji Fukunaga, Toshiyuki Kohara, Kazutoshi Watanabe, Yoshihiro Usui, Fumiaki Uehara, Satoshi Yokoshima, Daiki Sakai, Shin-ichi Kusaka, Kazuki Nakayama
  • Patent number: 8518939
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: August 27, 2013
    Assignees: Mitsubishi Tanabe Pharma Corporation, Sanofi
    Inventors: Kenji Fukunaga, Kazutoshi Watanabe, Pascal Barneoud, Jesus Benavides, Jeremy Pratt
  • Publication number: 20130165514
    Abstract: The present invention provides an orally administered composition and a dietary composition, which have a serum lipid improving effect. The orally administered composition and dietary composition, having a serum lipid improving effect, according to the present invention camp rise 2.0% by weight or less of a DHA ethyl ester composition comprising 75% by weight or more of DHA ethyl ester. It is preferable to comprise 1.2% by weight or less of the DHA ethyl ester composition. It is preferable not to substantially comprise a DHA ethyl ester composition comprising 30% by weight or less of DHA ethyl ester.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 27, 2013
    Applicant: BIZEN CHEMICAL CO., LTD.
    Inventors: Kenji Fukunaga, Yoshio Shimizu, Mikiya Takamoto, Teruyuki Kanada
  • Patent number: 8409325
    Abstract: There is disclosed an asymmetric gas separation membrane exhibiting both improved gas separation performance and improved mechanical properties, which is made of a soluble aromatic polyimide comprised of a repeating unit represented by general formula (1): wherein B in general formula (1) B comprises 10 to 70 mol % of tetravalent unit B1 represented by general formula (B1) and 90 to 30 mol % of tetravalent unit B2 represented by general formula (B2), and A in general formula (1) comprises 10 to 50 mol % of bivalent unit A1 represented by general formula (A1a) or the like and 90 to 30 mol % of bivalent unit A2 represented by general formula (A2a) or the like.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: April 2, 2013
    Assignee: Ube Industries, Ltd.
    Inventors: Toshimune Yoshinaga, Makoto Nakamura, Tomonori Kanougi, Yoji Kase, Kenji Fukunaga
  • Patent number: 8394176
    Abstract: Disclosed are a gas separation membrane and a gas separation method in which at least one species of organic vapor is separated and recovered from an organic vapor mixture using the gas separation membrane. The gas separation membrane is made of an aromatic polyimide composed of a tetracarboxylic acid component consisting of an aromatic ring-containing tetracarboxylic acid and a diamine component comprising 10 to 90 mol % of a combination of (B1) 3,4?-diaminodiphenyl ether and (B2) 4,4?-diaminodiphenyl ether at a B1 to B2 molar ratio, B1/B2, ranging from 10/1 to 1/10, and 10 to 90 mol % of other aromatic diamine.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: March 12, 2013
    Assignee: Ube Industries, Ltd.
    Inventors: Tomonori Kanougi, Harutoshi Hoshino, Toshimune Yoshinaga, Yoji Kase, Kenji Fukunaga
  • Publication number: 20120252812
    Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).
    Type: Application
    Filed: May 9, 2012
    Publication date: October 4, 2012
    Applicants: SANOFI-AVENTIS, MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kenji FUKUNAGA, Kazutoshi WATANABE, Pascal BARNEOUD, Jesus BENAVIDES, Jeremy PRATT